Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.

Human pluripotent stem cell-derived dopaminergic progenitors are safe for transplantation in Parkinson's disease patients, with no serious adverse events observed over 12 months.

• Why it matters: Parkinson's disease involves progressive loss of dopaminergic neurons, and current treatments do not restore lost cells, highlighting the need for regenerative therapies.
• What they did: Eight individuals with moderate PD received bilateral intraputaminal transplants of stem cell-derived dopaminergic progenitors at two dose levels, followed by 12 months of immunosuppression.
• The result: The trial demonstrated a favorable safety profile, with no graft-induced dyskinesias or tumor formation, supporting further research into stem cell-based regenerative treatments for PD.